Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.2%

49 terminated/withdrawn out of 942 trials

Success Rate

89.3%

+2.8% vs industry average

Late-Stage Pipeline

9%

84 trials in Phase 3/4

Results Transparency

11%

47 of 409 completed trials have results

Key Signals

109 recruiting47 with results31 terminated18 withdrawn

Enrollment Performance

Analytics

N/A
356(56.0%)
Phase 2
125(19.7%)
Phase 3
68(10.7%)
Phase 1
66(10.4%)
Phase 4
16(2.5%)
Early Phase 1
5(0.8%)
636Total
N/A(356)
Phase 2(125)
Phase 3(68)
Phase 1(66)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (942)

Showing 20 of 942 trials
NCT04106115Phase 1Recruiting

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Role: lead

NCT06975137Not ApplicableCompleted

Zithandani Stepping Stones and Creating Futures - Phase 2 Pilot

Role: collaborator

NCT07135271Not ApplicableNot Yet Recruiting

BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer

Role: lead

NCT07362433Phase 4Recruiting

Trial of an AI-enabled Digital Stethoscope to Improve Antibiotic Stewardship

Role: collaborator

NCT07112508Not ApplicableRecruiting

PRISM: The PRimary Care Individual Social Norms MSK Data Dashboard: a Feasibility Trial

Role: lead

NCT03050931Active Not Recruiting

Electrical Impedance Tomography of Epilepsy

Role: lead

NCT04685616Phase 3Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Role: lead

NCT05664854Not ApplicableRecruiting

Electrical Impedance Tomography & Selective Stimulation of Vagus Nerve

Role: lead

NCT02443831Phase 1Recruiting

CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

Role: lead

NCT02308072Phase 1Completed

Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer

Role: lead

NCT03684564Phase 2Completed

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

Role: lead

NCT03494322Phase 2Completed

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

Role: lead

NCT03430700Phase 2Completed

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Role: lead

NCT07597798Recruiting

EVERiST: Impact of Image Detected Accessory Pudendal Artery on Erection Recovery After Nerve Sparing Prostatectomy

Role: lead

NCT07541911Not ApplicableRecruiting

A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy

Role: lead

NCT07592247Not ApplicableNot Yet Recruiting

Potential for Recovery of Voluntary Finger Extension After Stroke

Role: lead

NCT07539259Phase 2Not Yet Recruiting

To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes

Role: lead

NCT07192705Recruiting

Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)

Role: lead

NCT03644303Not ApplicableCompleted

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

Role: collaborator

NCT07051408Active Not Recruiting

Predictors Of Cognitive Decline Using Digital Devices

Role: lead